Please assess the completion status of the following clinical trial:

Trial Title: A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Body Mass Index (BMI) of 17 to 40 kg/m2~* Subjects must have two comparable psoriatic lesions measuring between 9 and 100 cm2 and these target lesions must be similar in size to each other, and separated by at least 15 cm.~Exclusion Criteria:~* Subjects with lesions solely involving the palms of the hands or soles of the feet or intertriginous areas, the scalp or the face.~* Subjects with pustular psoriasis or erythroderma.~* Subjects currently on other topical agents or UVB therapy within 2 weeks of the first dose of study medication.~* Subjects receiving PUVA within 4 weeks of the first dose of study medication.~* Subjects receiving systemic retinoids, etanercept, adalimumab or efalizumab or oral immunosuppressives within 3 months prior to the first dose of study medication.~* Subjects receiving any other biological therapy (infliximab, alefacept, abatacept, etc) within 3 months of the first dose of study medication.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Cohort A: INCB018424 Ruxolitinib 0.5% (Type: EXPERIMENTAL): INCB018424 Ruxolitinib 0.5% vs vehicle applied once daily for 28 days
- Cohort B: INCB018424 Ruxolitinib 1.0% (Type: EXPERIMENTAL): INCB018424 Ruxolitinib 1.0% vs vehicle applied once daily for 28 days
- Cohort C: INCB018424 Ruxolitinib 1.5% (Type: EXPERIMENTAL): INCB018424 Ruxolitinib 1.5% vs vehicle applied twice for 28 days
- Cohort D: 18424 Ruxolitinib vs Dovonex® calcipotriene (Type: EXPERIMENTAL): INCB018424 up to 1.5% versus Dovonex® calcipotriene 0.005% cream applied BID for 28 days
- Cohort E: 18424 Ruxolitinib vs Diprolene® AF betamethasone diproprionate (Type: EXPERIMENTAL): INCB018424 up to 1.5% versus Diprolene ® AF betamethasone dipropionate 0.05% cream applied twice a day for 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).